Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630823 · ClinicalTrials.gov registry record · Phase 1
MK-3475 Immunotherapy in Endometrial Carcinoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02630823 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT02630823, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Due to the high expression of PD-L1 in endometrial cancers as well as in ovarian cancers which are molecularly similar to uterine serous cancers, using pembrolizumab should be beneficial in this patient population. Since the investigators are able to get a pre-treatment research- related endometrial biopsy as well as the surgical specimen post two cycles of pembrolizumab, the investigators will be able to evaluate the mechanism of action of this drug on the endometrial cancer tumor environment.
Interventions
- DRUG MK-3475
- PROCEDURE Surgical resection (standard of care)
- DRUG Paclitaxel (standard of care)
- DRUG Carboplatin (standard of care)
- RADIATION Radiation (standard of care)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02-05 |
| Est. Completion | 2020-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02630823
The ClinicalTrials.gov registry entry for NCT02630823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MK-3475 is the first listed.
NCT02630823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02630823 about?
NCT02630823 is a clinical study titled "MK-3475 Immunotherapy in Endometrial Carcinoma". Due to the high expression of PD-L1 in endometrial cancers as well as in ovarian cancers which are molecularly similar to uterine serous cancers, using pembrolizumab should be beneficial in this patient population. Since the investigators are able to get a pre-treatment research- related endometrial...
What is the current status of trial NCT02630823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-02-05. Estimated completion is 2020-10-03.
What interventions are being tested in trial NCT02630823?
The interventions under investigation include: MK-3475 (DRUG), Surgical resection (standard of care) (PROCEDURE), Paclitaxel (standard of care) (DRUG), Carboplatin (standard of care) (DRUG), Radiation (standard of care) (RADIATION).
Who is sponsoring clinical trial NCT02630823?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.